Judicial

#62023TJ1181Avrupa Genel Mahkemesi'nin (Dördüncü Dairesi) 11 Şubat 2026 tarihli kararı. Mylan Ireland Ltd - Avrupa Komisyonu. İnsan kullanımı için ilaçlar – Dimetil Fumarat Mylan'ın pazarlama izninin iptali – insan kullanımı için bir ilaç olan dimetil fumarat – Direktif 2001/83/EC – Tüzük (EC) No 726/2004 – TFEU Madde 266. Dava T-1181/23.

🇪🇺European Union··Other·Medium Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

The General Court ruled that the European Commission can revoke the marketing authorization for Dimethyl Fumarate Mylan, a medicine used for treating certain health conditions. This decision affects Mylan Ireland Ltd, the company that produces this medication, and potentially impacts patients who rely on it for treatment.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Revocation of marketing authorization for Dimethyl Fumarate Mylan
  • Compliance with Directive 2001/83/EC and Regulation (EC) No 726/2004
  • Implications for patient access to the medication

Affected Parties

Mylan Ireland LtdPatients using Dimethyl Fumarate

Tags

medicinal products,marketing authorization,European Commission…

More from European Union

EU Trade Mark Decision: Green Asset vs. EUIPO

General Court Decision on Inadmissibility of Access Info Europe v European Commission

Directive (EU) 2026/799 harmonising certain aspects of insolvency law